CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$46.85 USD
+1.46 (3.22%)
Updated Oct 11, 2024 03:59 PM ET
After-Market: $46.80 -0.05 (-0.11%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CRSP 46.85 +1.46(3.22%)
Will CRSP be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRSP
Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
Other News for CRSP
7 children given bluebird's Skysona developed blood cancer: study
Interest Rate Regimes And ARKG: Underperformance Explained
AstraZeneca, CSPC deal shows Lp(a) space remains hot, says BMO Capital
Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma
CRISPR Therapeutics Deserves its Lofty Valuation Even with Conservative Forecasts